vaccin
prevent
hpvassoci
cancer
although
tumor
express
foreign
viral
antigen
protein
littl
benefit
establish
malign
like
due
neg
environment
cue
block
tumor
recognit
induc
cell
anergi
vivo
postul
could
identifi
mechan
ex
vivo
stimul
cell
could
reactiv
expand
tumordirect
tcell
line
hpvposit
cancer
patient
subsequ
adopt
immunotherapi
total
patient
hpvassoci
cancer
studi
peripher
blood
cell
stimul
monocytederiv
dendrit
cell
load
pepmix
peptid
librari
overlap
aminoacid
span
presenc
absenc
specif
accessori
cytokin
result
tcell
line
expand
pepmixload
activ
bcell
blast
releas
cytotox
respons
assess
success
reactiv
expand
cell
cervic
oropharyng
cancer
patient
presenc
cytokin
critic
process
cell
line
possess
desir
characterist
polyclon
multipl
tcell
subset
represent
includ
memori
compart
h
bia
may
elimin
target
conclus
shown
possibl
robustli
gener
tcell
line
patient
cancer
techniqu
scalabl
goodmanufacturingprocedur
compliant
line
could
use
adopt
cellular
immunotherapi
patient
cancer
known
serotyp
human
papillomaviru
hpv
one
strongli
associ
squamou
cell
carcinoma
anogenit
tract
oropharynx
found
approxim
cervic
anal
penil
baseoftongu
tonsillar
cancer
us
alon
new
case
cancer
diagnos
annual
mani
hpvassoci
tumor
erad
multimod
therapi
recurr
diseas
extrem
poor
prognosi
although
hpv
vaccin
effect
prevent
mani
cancer
activ
establish
neoplasm
small
genom
approxim
kb
organ
earli
code
late
code
long
control
region
provir
integr
host
dna
critic
oncogenesi
lead
uncontrol
product
transform
protein
bind
prb
caus
degrad
inactiv
lead
genet
instabl
cell
carcinogenesi
point
structur
protein
target
current
hpv
vaccin
longer
express
despit
continu
express
viral
antigen
howev
prove
challeng
elicit
robust
immun
respons
antigen
patient
hpvassoci
cancer
precursor
cell
may
rare
difficult
expand
vivo
immuneinhibitori
cue
tumor
environ
may
block
initi
tumor
cell
recognit
subsequ
cell
activ
expans
persist
recent
shown
cytotox
lymphocyt
ctl
direct
even
weak
tumor
associ
antigen
gener
patient
peripher
blood
cell
vitro
addit
cytokin
revers
anergi
inhibit
expans
regulatori
cell
treg
promot
effector
cell
surviv
postul
could
identifi
similar
mechan
reactiv
cell
specif
cancerassoci
hpv
antigen
cell
use
therapi
patient
hpvassoci
malign
must
expand
number
suffici
administr
whilst
retain
represent
critic
tcell
subpopul
effector
memori
compart
requir
persist
includ
cell
cytotox
h
phenotyp
addit
polyclon
preferenti
target
multipl
epitop
antigen
avoid
tumor
escap
loss
singl
target
epitop
describ
robust
gmpcompliant
approach
major
patient
studi
produc
cell
desir
phenotyp
number
function
adopt
transfer
patient
hpvassoci
cancer
blood
healthi
volunt
patient
cervic
oropharyng
cancer
nonmetastat
stage
iiiva
obtain
inform
consent
protocol
approv
baylor
colleg
medicin
univers
texa
md
anderson
cancer
center
institut
review
board
peripher
blood
mononuclear
cell
pbmc
isol
gradient
centrifug
lymphoprep
axisshield
oslo
norway
use
gener
dendrit
cell
dc
cell
line
bcell
blast
bb
avail
paraffinembed
tumor
tissu
primari
lesion
nodal
metastasi
assess
presenc
dna
whole
sampl
dna
isol
digest
sampl
proteinas
k
use
standard
procedur
pcr
assay
util
amplifi
region
use
primer
gener
fragment
southern
blot
follow
hybrid
label
probe
specif
use
confirm
ident
amplifi
fragment
dc
gener
previous
describ
briefli
monocyt
isol
pbmc
select
use
mac
bead
miltenyi
biotec
bergisch
gladbach
germani
cultur
plate
cellswel
dc
medium
consist
cellgenix
medium
cellgenix
usa
antioch
il
mm
alanylglutamin
glutamax
invitrogen
carlsbad
ca
uml
granulocytemacrophagecoloni
stimul
factor
gmcsf
leukin
immunex
seattl
wa
uml
r
system
minneapoli
mn
day
gmcsf
replenish
day
day
dc
matur
dc
media
ngml
r
system
ngml
r
system
ngml
tumor
necrosi
r
system
prostaglandin
sigma
saint
loui
mo
uml
gmcsf
uml
dc
matur
assess
flow
cytometri
detect
upregul
hladr
overlap
peptid
librari
overlap
amino
acid
contain
possibl
hla
class
irestrict
epitop
mani
hla
class
iirestrict
epitop
uniprot
protein
id
purchas
jpt
technolog
berlin
germani
peptid
pool
contain
mixtur
individu
peptid
peptid
mixtur
pepmix
compris
individu
peptid
antigen
prepar
peptid
dissolv
dimethyl
sulfoxid
dmso
mgml
dc
load
pepmix
incub
min
pellet
matur
dc
dilut
pepmix
solut
ctl
medium
mixtur
rpmi
hyclon
logan
ut
click
medium
irvin
scientif
santa
ana
ca
supplement
human
ab
serum
valley
biomed
winchest
va
mm
alanylglutamin
excess
peptid
wash
serial
suspens
ctl
medium
centrifug
pbmc
first
stimul
peptideload
dc
stimulatortorespond
r
ratio
cell
cultur
concentr
ml
ctl
medium
pbmc
per
well
plate
without
supplement
ngml
ngml
r
system
ng
ml
r
system
ngml
r
system
day
cell
harvest
count
assess
viabil
use
trypan
blue
exclus
expand
concentr
ml
ctl
medium
cell
per
well
plate
second
stimul
r
ratio
freshli
prepar
pepmixload
dc
cocultur
supplement
proleukin
chiron
emeryvil
ca
uml
day
one
week
second
stimul
ctl
harvest
count
assess
viabil
use
trypan
blue
exclus
use
phenotyp
function
assay
expand
weekli
stimul
r
ratio
freshli
prepar
pepmixload
bb
see
presenc
ngml
initi
concentr
ml
ctl
medium
cell
per
well
plate
adenoviru
adv
cmvspecif
cell
line
establish
use
similar
protocol
substitut
adv
hexon
adv
penton
cmv
cmv
pepmix
jpt
technolog
epitheli
cell
line
atcc
manassa
va
transduc
retroviru
encod
previous
describ
transduc
cell
line
seed
per
well
plate
confluent
nearconflu
cell
irradi
gy
pbmc
pbmc
suspend
ctl
medium
cellsml
uml
cyclosporin
sandoz
holzkirchen
germani
plate
monolay
cell
per
well
medium
replenish
need
result
activ
b
cell
bb
collect
day
initi
cultur
resuspend
ctl
medium
ml
expand
weekli
plate
fresh
irradi
monolay
per
well
bb
load
pepmix
describ
dc
use
apc
third
subsequ
weekli
cell
stimul
pbmc
suspend
cellsml
complet
medium
rpmi
supplement
human
ab
serum
mm
alanylglutamin
pha
sigma
saint
loui
mo
cultur
well
plate
cell
per
well
hour
half
medium
exchang
fresh
complet
medium
ad
final
concentr
uml
process
repeat
twice
everi
hour
cell
subcultur
separ
well
number
cell
per
well
exceed
cell
pha
blast
harvest
pool
count
day
initi
cultur
frozen
aliquot
cell
one
three
day
use
cytotox
assay
pha
blast
thaw
wash
twice
complet
medium
resuspend
cell
ml
complet
medium
uml
plate
plate
cell
per
well
pha
blast
load
pepmix
describ
dc
use
apc
target
elispot
cytotox
assay
phycoerythrin
pe
fluorescein
isothiocyan
fitc
peridinin
chlorophyl
protein
percp
allophycocyanin
apc
conjug
hladr
monoclon
antibodi
use
stain
dc
cell
line
bb
pha
blast
appropri
antibodi
becton
dickinsonpharmingen
san
diego
ca
control
sampl
label
appropri
isotypematch
antibodi
includ
experi
cell
analyz
flow
cytomet
facscan
becton
dickinson
equip
filter
set
fluoresc
signal
interferongamma
elispot
analysi
use
quantifi
hpvspecif
cell
pbmc
tcell
line
dilut
cellswel
plate
measur
number
cell
secret
respons
stimul
pepmix
peptid
pool
singl
peptid
cultur
condit
test
duplic
neg
nopeptid
posit
staphylococc
enterotoxin
b
control
includ
experi
pepmix
survivin
ebv
latent
membran
protein
hiv
groupspecif
antigen
gag
multipl
isol
use
specif
control
experi
tcell
line
also
stimul
autolog
pha
blast
transduc
retroviru
encod
fluoresc
protein
gfp
fusion
protein
hour
incub
plate
develop
spot
previous
describ
dri
overnight
room
temperatur
dark
sent
zellnet
consult
new
york
ny
quantif
frequenc
cell
specif
antigen
express
specif
spotform
cell
sfc
per
input
cell
number
elispot
respons
consid
posit
least
sfc
per
cell
assay
twice
number
neg
control
cultur
analyz
repertoir
tcr
chain
cell
line
use
flow
cytometr
assay
iotest
beta
mark
immunotech
sa
marseil
franc
per
manufactur
instruct
analysi
detect
normal
human
tcr
repertoir
cytotox
specif
cell
line
measur
standard
cr
releas
assay
use
effectortotarget
e
ratio
target
cell
autolog
pha
blast
bb
load
pepmix
allogen
autolog
pha
blast
bb
alon
use
control
target
cell
label
simultan
hour
cr
percentag
specif
lysi
calcul
experiment
releas
spontan
releas
maximum
releas
spontan
releas
cell
line
dilut
cellswel
plate
virusspecif
activ
respond
cell
measur
direct
stimul
pepmix
overnight
incub
presenc
monensin
brefeldin
becton
dickinsonpharmingen
cell
stain
antibodi
permeabil
stain
fitcor
peconjug
antibodi
becton
dickinsonpharmingen
cocultur
cell
line
tumor
cell
line
caski
obtain
mix
viru
advcmv
specif
cell
caski
cell
multipl
e
cell
ratio
final
rel
proport
caski
cell
ctl
medium
cell
combin
aliquot
stain
antibodi
analyz
flow
cytometri
quantifi
baselin
proport
caski
doubli
cell
among
cell
cell
mixtur
plate
replic
well
plate
cellswel
day
incub
portion
well
trypsin
cell
stain
analyz
flow
cytometri
expansioncontract
tumor
cell
number
assess
percentag
caski
cell
cultur
time
point
normal
time
zero
numer
data
repres
mean
standard
deviat
fisher
exact
test
student
ttest
use
determin
statist
signific
differ
group
categor
continu
variabl
respect
signific
level
set
investig
presenc
cell
peripher
blood
healthi
individu
hpvassoci
cancer
patient
synthes
panel
peptid
overlap
amino
acid
aa
cover
aa
uniqu
sequenc
protein
respect
peptid
mixtur
pepmix
compris
possibl
hla
class
irestrict
epitop
mani
hla
class
iirestrict
epitop
antigen
ad
mononuclear
cell
isol
directli
peripher
blood
number
spotform
cell
sfc
measur
describ
method
found
evid
cell
individu
either
normal
patient
group
absenc
reactiv
could
due
true
nonrespons
cell
nonexist
cell
bear
tcr
recogn
epitop
polar
toward
nont
h
popul
insensit
elispot
method
low
finit
frequenc
precursor
cell
distinguish
possibl
stimul
pbmc
peptideload
dc
strategi
previous
allow
us
expand
thu
detect
low
frequenc
cell
specif
viral
antigen
even
condit
howev
sfc
detect
sinc
cervic
oropharyng
cancer
respect
associ
consist
lack
respons
even
patient
tumor
explain
simpli
lack
exposur
antigen
vivo
assert
support
detect
dna
tumor
patient
paraffinembed
biopsi
materi
avail
reason
instead
hpvspecif
cell
patient
hpvassoci
cancer
anerg
tumor
could
therefor
recov
potent
antigen
present
strategi
unless
happen
physic
delet
cell
ontogeni
patient
therefor
incorpor
cytokin
dct
cellpepmix
cultur
strategi
enabl
us
detect
reactiv
popul
cervic
oropharyng
cancer
patient
fig
well
normal
subject
shown
reactiv
defin
method
cycl
dc
stimul
correl
presenc
dna
tumor
sampl
vs
sampl
p
addit
signific
differ
sfc
respons
versu
neg
nopeptid
control
cell
line
patient
hpvposit
tumor
p
respect
signific
differ
cell
line
patient
hpvneg
tumor
p
respect
note
differ
also
signific
hpvindetermin
patient
p
respect
like
two
third
expect
tumor
correl
tumor
stage
amplitud
respons
investig
endogen
process
viral
antigen
recogn
pepmixstimul
cell
test
reactiv
autolog
pha
blast
transduc
retroviru
encod
antigen
found
cell
line
produc
elispot
assay
use
pepmix
react
ident
pha
blast
express
respect
fig
confirm
antigen
specif
cell
line
test
elispot
assay
irrelev
peptid
ebv
hiv
gag
survivin
signific
differ
sfc
respons
peptid
neg
nopeptid
control
p
respect
fig
henc
addit
appropri
cytokin
combin
select
expand
popul
cell
individu
hpvassoci
cancer
overcom
relianc
multipl
round
tcell
stimul
dc
would
often
unavail
suffici
number
scale
approach
clinic
use
substitut
activ
b
cell
bcell
blast
bb
antigen
present
cell
apc
modifi
previous
describ
approach
use
feeder
layer
upon
pbmc
grown
presenc
cyclosporin
condit
expand
autolog
b
cell
express
activ
marker
includ
hladr
fig
load
pepmix
use
weekli
stimul
hpvspecif
cell
initi
activ
pepmixload
dc
strategi
produc
fold
expans
hpvspecif
tcell
line
within
week
fig
averag
maximum
fold
expans
per
round
bb
stimul
stimul
bb
induc
increas
total
cell
number
rais
percentag
cell
demonstr
expans
antigenspecif
fig
phenotyp
analysi
bulk
cell
line
show
compos
almost
exclus
cell
cell
compris
variabl
proport
cell
depend
patient
fig
cell
display
predominantli
effector
memori
phenotyp
also
includ
cell
express
memoryactiv
marker
rang
rang
natur
killer
nk
cell
median
line
express
multipl
tcell
receptor
tcr
famili
establish
polyclon
fig
next
character
epitop
specif
cell
line
combin
individu
peptid
pool
contain
distinct
peptid
individu
peptid
uniqu
repres
pool
reactiv
detect
within
specif
pair
peptid
pool
line
rescreen
pertin
individu
use
individu
peptid
nonreact
pool
neg
control
fig
method
reveal
multipl
epitop
recogn
within
antigen
tabl
show
presenc
accessori
cytokin
result
nonspecif
activ
cell
sinc
individu
line
could
recogn
multipl
epitop
antigen
least
one
epitop
antigen
studi
confirm
line
function
well
phenotyp
fig
polyclon
although
cell
line
made
consist
releas
respons
viral
peptid
fig
contain
cell
test
tcell
line
directli
cytotox
pepmixload
autolog
pha
blast
bb
short
term
chromium
releas
assay
fig
kill
increas
extend
assay
hour
investig
sever
cell
line
weak
cytotox
activ
chromium
releas
assay
contrast
mark
respons
elispot
use
intracellular
stain
presenc
absenc
pepmix
stimul
determin
cell
subset
respons
antigen
observ
andor
cell
compart
cell
cytokineposit
fig
addit
signific
releas
h
cytokin
fig
thu
limit
direct
cytotox
cell
line
like
repres
predomin
recognit
hpv
antigen
h
cell
investig
potenti
antitumor
activ
hpvdirect
line
cocultur
hpvspecif
tcell
line
two
patient
cervic
cancer
cell
line
caski
tcell
line
chosen
recogn
epitop
tihdiilec
tledllmgt
presum
restrict
accord
peptid
predict
softwar
http
wwwbimascitnihgovmolbio
hlabind
cell
transient
control
growth
caski
cell
fig
confirm
potenti
react
tumor
even
recognit
occur
singl
hlarestrict
locu
establish
cell
line
consist
expand
blood
patient
tumor
scalabl
gmpcompliant
techniqu
use
specif
accessori
cytokin
dc
activ
b
cell
although
could
confirm
tumor
posit
patient
sever
studi
shown
preval
cervic
cancer
specif
type
head
neck
cancer
studi
oropharyng
base
tongu
least
respect
moreov
even
exclud
patient
unknown
tumor
statu
limit
analysi
known
posit
neg
case
data
still
strongli
support
differ
pattern
cell
respons
neg
tumor
patient
therefor
believ
tcell
line
expand
repres
true
immun
respons
viral
antigen
data
show
line
may
grown
clinic
use
number
possess
desir
characterist
multipl
tcell
subset
represent
includ
memori
compart
h
bia
result
demonstr
line
compris
polyclon
popul
cell
react
multipl
epitop
therefor
must
contain
polyspecif
polyclon
effector
cell
although
individu
gener
specif
analysi
multipl
clone
would
provid
extens
data
compon
clonal
respons
would
chang
conclus
current
cure
rate
hpvassoci
tumor
cervix
oropharynx
lower
desir
recurr
diseas
dismal
prognosi
although
hpvassoci
tumor
express
viral
antigen
patient
immun
respons
virusinfect
cell
limit
extent
efficaci
immun
peptid
may
result
regress
hpvassoci
precancer
lesion
individu
effort
activ
immun
patient
whose
infect
progress
cancer
fail
gener
signific
antitumor
activ
remark
given
signific
viral
antigen
exposur
consist
observ
mani
group
hpvspecif
circul
cell
present
low
undetect
number
patient
noteworthi
similar
lack
effect
antitumor
immun
observ
subject
ebvassoci
malign
natur
occur
cell
specif
virusderiv
antigen
unabl
control
erad
lymphoma
nasopharyng
cancer
patient
nevertheless
autolog
ebvspecif
ctl
gener
ex
vivo
infus
even
small
number
cell
produc
complet
sustain
remiss
demonstr
feasibl
test
similar
approach
patient
hpvposit
cancer
poor
tcell
respons
hpv
antigen
vivo
may
due
failur
antigen
present
due
inadequ
antigen
process
lack
costimul
apc
inadequ
traffick
effector
cell
tumor
site
polar
immun
respons
effector
regulatori
subset
advers
effect
immun
may
revers
vitro
previous
observ
addit
accessori
cytokin
tcell
dc
cocultur
allow
emerg
cell
respons
poorli
immunogen
target
combin
cytokin
use
purpos
chosen
base
complementari
natur
activ
valid
empir
inhibit
convers
progenitor
cell
regulatori
tlymphocyt
prevent
activ
induc
cell
death
like
import
set
induc
h
respons
enhanc
cytotox
cell
rescu
anerg
cell
restor
activ
tumor
associ
antigen
henc
addit
cytokin
cultur
allow
us
expand
activ
cell
low
frequenc
like
anerg
use
pepmix
specif
cytokin
gener
cell
line
cancer
patient
investig
exploit
method
rapidli
select
enrich
cell
stimul
pbmc
long
peptid
howev
contrast
approach
line
gener
virusexpos
healthi
donor
would
hladispar
cancer
patient
requir
therapi
adopt
transfer
plan
moreov
cell
line
grown
use
cell
growth
factor
poorli
defin
sourc
cytokin
readili
made
gmpcompliant
scale
measur
antitumor
activ
cell
line
use
autolog
target
puls
relev
antigen
although
cocultur
tumor
target
would
optim
assay
readili
establish
major
patient
sinc
syngen
hlamatch
tumor
cell
line
avail
assay
minor
cell
line
directli
cytotox
target
cell
like
major
hpvreactiv
cell
expand
cell
line
rather
cytotox
effector
cell
nonetheless
even
though
cell
may
immedi
effector
tumor
cell
destruct
tcr
engag
virustumor
specif
cell
also
play
import
role
provid
helper
activ
delay
cytotox
activ
inde
previous
observ
signific
clinic
antitumor
antivir
respons
administr
predominantli
ebv
adenovirusspecif
line
patient
ebvposit
lymphoma
adenovir
infect
mechan
effect
synergi
cell
dissect
murin
model
even
though
cell
may
directli
indirectli
clear
tumor
cell
express
viral
deriv
antigen
one
concern
adopt
transfer
approach
cell
may
nonetheless
becom
inact
elimin
vivo
sinc
reexpos
hostil
microenviron
prevent
spontan
emerg
immun
evas
strategi
virus
tumor
includ
product
cytokin
inhibit
activ
prolifer
effector
cell
one
wide
use
mechan
secret
transform
growth
factor
beta
ubiquit
cytokin
pleiotrop
effect
cell
growth
differenti
play
signific
role
maintain
tcell
homeostasi
inhibit
cell
prolifer
progress
premalign
lesion
associ
infect
cervic
intraepitheli
neoplasia
result
increas
express
one
isoform
among
immunosuppress
cytokin
may
also
deriv
treg
significantli
increas
drain
lymph
node
patient
advanc
cervic
cancer
circul
head
neck
cancer
patient
genet
modifi
ctl
ex
vivo
render
resist
immun
inhibitori
effect
necessari
strategi
could
appli
cell
line
addit
neg
growth
surviv
signal
effect
adopt
transfer
virusspecif
ctl
may
also
limit
poor
capac
expand
vivo
system
administr
cytokin
may
enhanc
surviv
transfer
antigenspecif
ctl
associ
seriou
side
effect
limit
amount
durat
treatment
moreov
favor
expans
unwant
cell
subset
treg
also
express
advers
affect
function
ctl
contrast
cytokin
play
essenti
role
homeostat
expans
cell
includ
memori
cell
acceler
immun
reconstitut
mous
model
decreas
number
treg
induc
apoptosi
coadministr
cytokin
may
thu
also
protect
cell
inhibitori
effect
tumor
microenviron
believ
cell
gener
procedur
potenti
foundat
clinic
trial
evalu
virusspecif
cell
therapi
hpvassoci
tumor
success
similar
strategi
may
benefici
tumor
express
nonvir
tumor
associ
antigen
patient
pbmc
stimul
twice
autolog
dc
load
pepmix
without
accessori
cytokin
releas
cultur
cell
quantifi
elispot
assay
stimul
result
line
pepmix
absenc
cytokin
sfc
spot
form
cell
pepmix
pepmix
neg
nopeptid
control
combin
individu
overlap
peptid
span
shown
pool
contain
distinct
peptid
individu
peptid
repres
pool
pinpoint
peptid
region
contain
epitop
question
reactiv
detect
within
specif
pair
peptid
pool
b
line
patient
opa
shown
panel
b
c
rescreen
pertin
individu
use
individu
peptid
nonreact
pool
neg
control
c
method
reveal
put
epitop
contain
particular
region
antigen
aa
opa
approach
show
individu
line
could
recogn
multipl
epitop
antigen
least
one
epitop
antigen
confirm
line
function
polyclon
anoth
exampl
patient
ott
shown
panel
df
pool
pool
individu
peptid
respect
perform
chromium
releas
assay
autolog
target
pha
blast
pha
bblast
bb
load
pepmix
irrelev
peptid
approxim
one
quarter
cell
line
robust
differenti
kill
autolog
target
display
without
allogen
kill
shown
opa
b
cell
line
cytotox
assay
produc
h
cytokin
shown
exposur
antigen
activ
mediat
almost
exclus
cell
c
cell
line
produc
h
cytokin
respons
antigen
p
versu
neg
control
p
